Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02134717
Other study ID # U01HL112711
Secondary ID
Status Terminated
Phase N/A
First received April 30, 2014
Last updated January 17, 2018
Start date January 2014
Est. completion date May 2015

Study information

Verified date January 2018
Source University of Pittsburgh
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study hypothesizes that inhibition of the receptor CCR5 by maraviroc will diminish inflammation in patients with sarcoidosis. Subjects with active sarcoidosis will first undergo bronchoscopy with bronchoalveolar lavage to recover lung immune cells for baseline analysis. They will then receive the drug maraviroc for 6 weeks duration. They will then undergo a repeat bronchoscopy with bronchoalveolar lavage to recover lung immune cells for analysis following maraviroc treatment.


Description:

The investigators hypothesize that inhibition of CCR5 by maraviroc may have a beneficial immunomodulatory effect on the granulomatous inflammation of pulmonary sarcoidosis. The specific aim of this proposal is the investigate the effect of CCR5 inhibition on the trafficking of mononuclear cells to the lung, skin, peripheral blood in subjects with active sarcoidosis exposed to the CCR5 inhibitor, maraviroc. A second aim will be to isolate by cell sorting cluster of differentiation 4 (CD4)+CCR5+ T cells for amplified gene expression profiling before and after CCR5 inhibition, experiments the investigators believe will elucidate genes associated with downstream activation and inhibition of CCR5 receptor function.


Recruitment information / eligibility

Status Terminated
Enrollment 3
Est. completion date May 2015
Est. primary completion date May 2015
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria:

1. Histologically proven sarcoidosis from any site (noncaseating granulomas without other causes).

2. Diagnosis of active sarcoidosis (Sec. 5.5.4.t) clinical stage II by Chest X-ray (CXR).

3. Forced Vital Capacity (FVC) >45% and Diffusing Capacity for Carbon Monoxide (DLCO) >50% of predicted values.

4. Evidence of active sarcoidosis (see criteria above)

5. Able and willing to complete all study procedures (e.g., bronchoscopy, post-drug surveillance)

6. Age: 18+ years old (prevalence greatest in young adults; pediatric maraviroc safety not established).

7. Not on immunosuppression for sarcoidosis at the time of recruitment, (e.g., steroids, tumor necrosis factor alpha (TNF-a) blockade)

8. Liver function (transaminases, bilirubin), coagulation (International Normalized Ratio (INR), partial thromboplastin time (PTT), platelet count), blood urea nitrogen (BUN), creatinine, and white blood count (WBC) within normal limits.

9. If female: negative pregnancy test, agreement to use reliable contraception if of childbearing potential 30 days prior and for 30 days after study completion (drug safety during pregnancy not established).

10. Negative HIV and HBsAg tests

Exclusion Criteria:

1. Diagnosis of infection based upon clinical evaluation and/or microbial testing.

2. The diagnosis of any disease involving the heart, lungs, liver (HVC), kidney, hematologic, endocrine, or Gl systems which, in the judgment of the PI, would pose an undue risk to the subject if they participated in this study. This includes but is not limited to diabetes, uncontrolled hypertension, liver disease (HVC), or history of malignancy.

3. Medications that will either inhibit or induce CYP3A4 (including St John's Wort)

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
all subjects will receive maraviroc 300mg orally twice a day for 6 weeks

Procedure:
Bronchoscopy with bronchoalveolar lavage
Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
venipunctures
Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
Skin biopsy
For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.

Locations

Country Name City State
United States Dorothy P. and Richard P. Simmons center for Interstitial lung Disease at the University of Pittsburgh Pittsburgh Pennsylvania

Sponsors (2)

Lead Sponsor Collaborator
Kevin F. Gibson University of Pittsburgh

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Total Cell Count and Differentials in Blood and Bronchoalveolar Lavage Fluid Pre- and Post Maraviroc General indicators of inflammation following chemokine receptor 5 (CCR5) inhibition in blood and bronchoalveolar lavage 6 weeks
Secondary Mononuclear Cell (MNC) Activation and T-cell Differentiation MNC activation and T-cell differentiation before and after CCR5 inhibition. 6 weeks
Secondary Chemokine Receptor 5 (CCR5) Expression Among These Immune Effector Cells CCR5 expression among these immune effector cells before and after CCR5 inhibition. 6 weeks
See also
  Status Clinical Trial Phase
Completed NCT04008069 - Sarilumab in Patients With Glucocorticoid-Dependent Sarcoidosis Phase 2
Recruiting NCT02807025 - Nasal, Tracheal and Bronchial Mucosal Lining Fluid(MLF) Sampling From Patients With Respiratory Diseases N/A
Completed NCT01615484 - Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability N/A
Completed NCT00326534 - Rickettsial Genesis to Sarcoidosis in Denmark N/A
Completed NCT00274352 - A Study of Adalimumab to Treat Sarcoidosis of the Skin Phase 2
Completed NCT00373555 - Endobronchial Ultrasonography in the Diagnosis of Sarcoidosis N/A
Recruiting NCT00470327 - A Study of the Natural Progression of Interstitial Lung Disease (ILD)
Completed NCT00512967 - The Occurence of Inflammation and Oxidative Stress in Lung Diseases N/A
Recruiting NCT01745237 - Delayed-Enhancement Cardiovascular Magnetic Resonance in Patients With Sarcoidosis
Completed NCT00369980 - Diagnostic Usefulness of Fluorine–18-α–Methyltyrosine PET in Combination With 18F-FDG in Sarcoidosis Patient N/A
Completed NCT00366509 - Role of Helicobacter Pylori and Its Toxins in Lung and Digestive System Diseases
Completed NCT00379275 - Eye and Immunogenetic Features of Sarcoidosis N/A
Completed NCT06396910 - TB and Sarcoidosis Granuloma
Completed NCT04156789 - Obstructive Sleep Apnoea in Sarcoidosis
Recruiting NCT02916459 - EBUS-TBNA vs Flex 19G EBUS-TBNA N/A
Recruiting NCT02827734 - Evaluation of Novel Lung Function Parameters in Patients With Interstitial Lung Disease (ILD)
Completed NCT02546388 - Somatostatin Receptor Imaging in Patients With Suspected Cardiac Sarcoidosis N/A
Completed NCT01687517 - Efficacy and Safety of Influenza Vaccine During Sarcoidosis Phase 3
Completed NCT01139710 - Sarcoidosis-associated Pulmonary Hypertension N/A
Terminated NCT00747461 - Interventional Cryotherapy for the Eradication of Benign Airway Disease ("ICE the BAD") Phase 4